Prostate Cancer

From FDA news to today’s top performers and entertainers, here’s what’s making headlines in the cancer space this week.

In topline findings from the phase 3 TITAN trial (NCT02489318) announced today by Janssen, Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus placebo in patients with metastatic castration-sensitive prostate cancer.

A prostate cancer survivor offers his thoughts on what you should (and shouldn't) say to someone who was recently diagnosed.

Men with advanced prostate cancer may benefit from genomic testing as BRCA and other gene mutations play a bigger role in guiding treatment.

Whether you call it No Shave November, Movember or Novembeard, it's important to remember it's all about men's health.

Most men with the disease should keep their prostates, says the author of a book about prostate cancer staging and treatment.

A clinical trial will test a radiation regimen designed to preserve sexual function in men being treated for prostate cancer.

It's more than the beard. It's about men's health.

A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

Here are the top 5 CURE stories for September 2018.

Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.

Family history was one indicator that a man should undergo periodic screening, but it wasn’t until a couple of decades ago that scientists confirmed a link between inherited mutations of the BRCA gene and the development of prostate cancer.

Here's how one expert decides on the next steps in treatment when a man with prostate cancer has a rising PSA and no visible metastases.

Take a look at the top five CURE stories of June 2018 in this video.

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

There are some key discussions that men with metastatic prostate cancer should have with their health care providers.

It is important that advocacy organizations unify their message, says Mike Crosby, the founder of the Veterans Prostate Cancer Awareness group.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Over the past few decades, prostate cancer has become better understood and treated more effectively.

The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC), according to Sun Pharma, the company commercializing the treatment.

The group came together to discuss gaps in knowledge concerning the prostate cancer journey, including nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic disease.

As part of the Prostate Cancer Foundation’s first annual campaign, Kristen Bell selected two winners because of their ‘candor and honesty’ to be honored.

Women felt that they could not show emotions of fear or vulnerability in front of their husbands or children.

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

With just one catwalk, the Prostate Cancer Foundation brought together celebrities, fashion designers and a special patient advocate to raise awareness for prostate cancer.